Sponsors (10)
The bill strengthens oversight, reporting, and data-sharing to detect and prevent contaminated infant formula and improve response and transparency, but it raises compliance costs, proprietary disclosure risks, workload/funding needs for FDA, and a nontrivial risk of short-term supply disruptions.
Parents and infants: Faster mandatory reporting, required sharing of isolates/genetic sequences, and quicker FDA actions enable earlier detection and more precise recalls of contaminated infant formula, reducing illness risk.
Public and stakeholders: Clear timelines for FDA responses and periodic reporting increase transparency and accountability, helping restore public confidence and allowing Congress to target fixes or resources where needed.
Parents and caregivers: Improved supply-chain oversight and interagency coordination (e.g., with USDA) improves the government's ability to prevent or respond to shortages and protect infant access to formula.
Manufacturers (especially small businesses): Faster reporting, testing, disposal, and documentation requirements increase compliance costs and operational burdens.
Parents and infants: Immediate cease-distribution and disposal requirements could cause short-term supply disruptions and temporary infant formula shortages.
Manufacturers: Mandated sharing of isolates, genetic sequences, and detailed supply-chain data and congressional reporting could expose proprietary or competitively sensitive business information.
Based on analysis of 3 sections of legislative text.
Introduced January 28, 2025 by Gary C. Peters · Last progress January 28, 2025
Requires infant formula manufacturers to notify FDA within one business day after a confirmed positive microbial test on a production aggregate sample and to cooperate immediately with FDA on stopping distribution, disposing of affected product, sharing test results and isolates/genetic sequences, and documenting investigations and corrective actions. Directs FDA to respond quickly, verify manufacturers’ investigations within 90 days, and makes documentation available electronically and for inspection. Also requires FDA to produce a progress report within 180 days on implementing a prior national infant formula resiliency strategy, begin supply-chain data reporting within 270 days and then quarterly for five years, consult with USDA and other agencies, and publish stakeholder-informed reports at 1, 3, and 5 years identifying best practices to improve safety and supply resiliency.